Corcept Therapeutics (CORT) Enterprise Value (2010 - 2026)

Corcept Therapeutics has reported Enterprise Value for 17 years, with the latest figure at -$308.2 million in Q2 2026.

• Quarterly Enterprise Value rose 9.94% year-over-year to -$308.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$308.2 million (up 9.94% YoY) and the FY2025 annual result came in at -$372.2 million, up 2.92% from the prior year.
• Enterprise Value climbed to -$308.2 million in Q2 2026 per CORT's latest filing, from -$338.2 million in the prior quarter.
• Over five years, Enterprise Value peaked at -$308.2 million in Q2 2026 and troughed at -$473.2 million in Q2 2024.
• A 5-year average of -$380.5 million and a median of -$371.1 million in 2022 frame the typical range for Enterprise Value.
• The sharpest annual moves came in 2022 and 2025: Enterprise Value plunged 93.11% in 2022, then rose 27.67% in 2025.
• Over 5 years, Enterprise Value stood at -$431.7 million in 2022, then gained by 14.7% to -$368.2 million in 2023, then decreased by 4.1% to -$383.3 million in 2024, then grew by 2.92% to -$372.2 million in 2025, then increased by 17.19% to -$308.2 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered -$308.2 million, -$338.2 million, and -$372.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.